<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Br J Pharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Br. J. Pharmacol</journal-id>
<journal-id journal-id-type="doi">10.1111/(ISSN)1476-5381</journal-id>
<journal-id journal-id-type="publisher-id">BPH</journal-id>
<journal-title-group>
<journal-title>British Journal of Pharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0007-1188</issn>
<issn pub-type="epub">1476-5381</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27339818</article-id>
<article-id pub-id-type="pmc">4978157</article-id>
<article-id pub-id-type="doi">10.1111/bph.13540</article-id>
<article-id pub-id-type="publisher-id">BPH13540</article-id>
<article-id pub-id-type="other">2016-BJP-0242-RP.R2</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Research Paper</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Research Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>
<italic>Magel2</italic>‐null mice are hyper‐responsive to setmelanotide, a melanocortin 4 receptor agonist</article-title>
<alt-title alt-title-type="right-running-head">Setmelanotide in <italic>Magel2</italic> mice</alt-title>
<alt-title alt-title-type="left-running-head">J M Bischof et al.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="bph13540-cr-0001">
<name>
<surname>Bischof</surname>
<given-names>Jocelyn M</given-names>
</name>
<xref ref-type="aff" rid="bph13540-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bph13540-cr-0002">
<name>
<surname>Van Der Ploeg</surname>
<given-names>Lex H T</given-names>
</name>
<xref ref-type="aff" rid="bph13540-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bph13540-cr-0003">
<name>
<surname>Colmers</surname>
<given-names>William F</given-names>
</name>
<xref ref-type="aff" rid="bph13540-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="bph13540-cr-0004">
<name>
<surname>Wevrick</surname>
<given-names>Rachel</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3343-5794</contrib-id>
<xref ref-type="aff" rid="bph13540-aff-0001">
<sup>1</sup>
</xref>
</contrib>
</contrib-group>
<aff id="bph13540-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Medical Genetics</named-content>
<institution>University of Alberta</institution>
<named-content content-type="city">Edmonton</named-content>
<named-content content-type="country-part">AB</named-content>
<country country="CA">Canada</country>
</aff>
<aff content-type="private-address" id="bph13540-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Rhythm Pharmaceuticals</institution>
<named-content content-type="city">Boston</named-content>
<named-content content-type="country-part">MA</named-content>
<country country="US">USA</country>
</aff>
<aff id="bph13540-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Pharmacology</named-content>
<institution>University of Alberta</institution>
<named-content content-type="city">Edmonton</named-content>
<named-content content-type="country-part">AB</named-content>
<country country="CA">Canada</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label>
Correspondence Rachel Wevrick, Department of Medical Genetics, University of Alberta, Edmonton, AB, Canada. E‐mail: <email>rwevrick@ualberta.ca</email><break></break></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>27</day>
<month>7</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>9</month>
<year>2016</year>
</pub-date>
<volume>173</volume>
<issue>17</issue>
<issue-id pub-id-type="doi">10.1111/bph.v173.17</issue-id>
<fpage>2614</fpage>
<lpage>2621</lpage>
<history>
<date date-type="received">
<day>31</day>
<month>3</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>14</day>
<month>6</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>6</month>
<year>2016</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2016 The British Pharmacological Society <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2016 The British Pharmacological Society</copyright-statement>
</permissions>
<self-uri content-type="pdf" xlink:href="file:BPH-173-2614.pdf" xlink:type="simple"></self-uri>
<abstract>
<sec id="bph13540-sec-0001">
<title>Background and Purpose</title>
<p>α‐ and β‐melanocyte‐stimulating hormones (MSH) are derived from pro‐opiomelanocortin (POMC) and are the natural agonist ligands of the melanocortin 4 receptor, a key regulator of energy homeostasis. Recent rodent and human data have implicated the <italic>MAGEL2</italic> gene, which may regulate activation of POMC neurons, as a significant contributor to the metabolic symptoms observed in Prader–Willi Syndrome (PWS). Firstly, patients with protein truncating mutations in <italic>MAGEL2</italic> exhibit numerous clinical characteristics of PWS. Secondly, <italic>Magel2</italic>‐null mice may not normally activate MC<sub>4</sub> receptors, as they are defective in the activation of their POMC neurons and hence may fail to normally release the POMC‐derived MC<sub>4</sub> receptor agonist ligands α‐ and β‐MSH. <italic>Magel2</italic>‐null mice represent a tractable animal model for the metabolic and appetitive imbalance seen in patients with PWS.</p>
</sec>
<sec id="bph13540-sec-0002">
<title>Experimental Approach</title>
<p>We tested a dose titration of the MC<sub>4</sub> receptor agonist setmelanotide, in development for rare monogenic forms of obesity, in <italic>Magel2</italic>‐null mice.</p>
</sec>
<sec id="bph13540-sec-0003">
<title>Key Results</title>
<p>We show that <italic>Magel2</italic>‐null mice are hypersensitive to the appetite suppressing and metabolic effects of setmelanotide.</p>
</sec>
<sec id="bph13540-sec-0004">
<title>Conclusion and Implications</title>
<p>Setmelanotide may be a useful investigational hormone/neuropeptide replacement therapy for PWS and rare monogenic forms of obesity exhibiting impaired function of POMC neurons.</p>
</sec>
</abstract>
<counts>
<page-count count="8"></page-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>bph13540</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>September 2016</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.4 mode:remove_FC converted:08.08.2016</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<p content-type="self-citation">
<mixed-citation id="bph13540-cit-0000" publication-type="journal">
<string-name>
<surname>Bischof</surname>, <given-names>J. M.</given-names>
</string-name>, <string-name>
<surname>Van Der Ploeg</surname>, <given-names>L. H. T.</given-names>
</string-name>, <string-name>
<surname>Colmers</surname>, <given-names>W. F.</given-names>
</string-name>, and <string-name>
<surname>Wevrick</surname>, <given-names>R.</given-names>
</string-name> (<year>2016</year>) <article-title>
<italic>Magel2</italic>‐null mice are hyper‐responsive to setmelanotide, a melanocortin 4 receptor agonist</article-title>. <source/>British Journal of Pharmacology, <volume>173</volume>: <fpage>2614</fpage>–<lpage>2621</lpage>. doi: <ext-link ext-link-type="doi" xlink:href="10.1111/bph.13540">10.1111/bph.13540</ext-link>.<pub-id pub-id-type="pmid">27339818</pub-id></mixed-citation>
</p>
</notes>
</front>
</article>
</pmc-articleset>